UnitedHealth Group (UNH) Shares Sharply Down Again After CEO Resignation, 2025 Guidance Suspension; Securities Class Action Pending - Hagens Berman

San Francisco, California--(Newsfile Corp. - May 13, 2025) - On May 13, 2025, investors in UnitedHealth Group (NYSE: UNH) saw the price of their shares crater as much as $65.71 (-17%) after the company announced that its CEO Andrew Witty has stepped down and that it pulled its 2025 guidance which the company issued less than one month ago.

This latest development follows the filing of a securities class action lawsuit styled Faller v. UnitedHealth Group Inc., et al., No. 1:25-cv-03799 (S.D.N.Y.), which was filed after roughly $170 billion of UnitedHealth's market capitalization was erased on April 17, 2025. The lawsuit seeks to represent investors who purchased UnitedHealth securities between December 3, 2024 and April 16, 2025.

Hagens Berman urges UnitedHealth investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.

Class Period: Dec. 3, 2024 - Apr. 16, 2025
Lead Plaintiff Deadline: July 7, 2025
Visit: www.hbsslaw.com/investor-fraud/unh
Contact the Firm Now: UNH@hbsslaw.com
844-916-0895

UnitedHealth Group Inc. (UNH) Securities Class Action:

The lawsuit focuses on the propriety of UnitedHealth's guidance for FY 2025 net EPS of $28.15 to $28.65 and adjusted EPS of $29.50 to $30.00. The company first provided this guidance on December 3, 2024, reiterated it on January 16, 2025, and slashed it on April 17, 2025. Then, less than a month later, on May 13, 2025, the company pulled its April 17 guidance in its entirety.

In less than a month, UnitedHealth investors have seen a substantial amount of the company's market capitalization wiped out.

The complaint alleges that UnitedHealth made false and misleading statements while failing to disclose crucial information to investors. The lawsuit claims that:

• UnitedHealth had, for years, engaged in a corporate strategy of denying health coverage in order to boost profits and its share price;
• This anti-consumer (and at times unlawful) strategy resulted in Senate and regulatory scrutiny over- and public angst against- UnitedHealth, and allegedly led to the murder of Brian Thompson, the CEO of UnitedHealthcare (the insurance arm of UnitedHealth), on December 4, 2024;
• Animus toward UnitedHealth was such that, after the murder of Mr. Thompson, many Americans openly celebrated his demise, praised his killer, and/or otherwise demanded that UnitedHealth change its strategy even if they condemned Mr. Thompson's killing;
• The foregoing regulatory and public outrage caused UnitedHealth to change its corporate practices of heightened coverage denials; and
• Notwithstanding the foregoing, UnitedHealth recklessly reiterated the guidance first given on December 3, 2024, the day before Mr. Thompson's murder, which was unrealistic considering the company was changing its corporate strategies.

Investors learned the truth on April 17, 2025, when UnitedHealth slashed the aforementioned guidance to net EPS of $24.65 to $25.15 and adjusted EPS of $26.00 to $26.50, and blamed the cuts on sudden increased care utilization among Medicare Advantage members.

This news sent the price of UnitedHealth shares crashing 22% lower on April 17, 2025, with one analyst reportedly commenting "'[w]hat that would suggest to me is that United and maybe the industry pulling back on prior authorizations, on the kind of the, intensity of some of the activity they do to manage utilization which obviously causes a bunch of consumer dissatisfaction.'"

"We're investigating whether, unknown to investors, UnitedHealth may have quietly changed its corporate strategies in its utilization management and, if so, whether that should have reasonably been taken into account when twice issuing its 2025 guidance," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in UnitedHealth and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now »

If you'd like more information and answers to frequently asked questions about the UnitedHealth Group case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding UnitedHealth should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email UNH@hbsslaw.com.

# # #

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252057